Application Abstract): The DUMC would join the ACTG and endeavor to accomplish the common goal of developing and implementing hypothesis-driven, pathogenesis-based innovative clinical trials for persons with HIV infection. The basic and clinical science investigators of Duke University offer to the ACTG a wide array of expertise, collaborative efforts, and a commitment to HIV clinical trials. The proposed basic and clinical investigators have expertise in areas of immune reconstitution/immune-based therapeutics, primary disease therapeutics, treatment and prevention of opportunistic infections (OI), oncology treatment research and neurology treatment research. Duke investigators are especially focused on immune reconstitution through a multidisciplinary collaboration involving immunologists, virologists, gene therapists, hematologist/oncologists and infectious disease physicians. The goals of the current research agenda include the design and testing of strategic interventions that achieve the prolonged suppression of HIV, decrease the HIV burden in lymphoid tissue, and restored immune function. To ensure the integration of the diverse basic and clinical scientific researchers into the Adult ACTU, a local Scientific Advisory Board (SAB) composed of key investigators from these groups will guide the research agenda. The extensive pre-clinical research endeavor at Duke is further complemented by a critical infrastructure for the performance of clinical trials. Over 700 subjects have been enrolled into 50 HIV-related clinical trials at Duke since 1987. The investigators have specifically emphasized their participation in Phase I clinical trials, having participated in the ACTG as a subunit of the University of Alabama at Birmingham (UAB) Adult ACTU since the last ACTG recompetion. Duke University has also maintained an active clinical research agenda outside the ACTG. The proposed catchment area for the ACTU would include the expanding HIV- positive patient population which reflects the Southeastern U.S. HIV epidemic. Seropositive individuals and persons at high risk of HIV infection are catalogued in a clinical database to facilitate subject recruitment. Active outreach programs and the Community Advisory Board (CAB) assist in enrolling women and minorities into clinical trials. The North Carolina Children's AIDS Network (NC-CAN) is coordinated through Duke University and the NC-CAN ACTU is available for collaborative clinical studies for mothers/infants who are HIV exposed/infected. The Adult ACTU will cooperate in fulfilling the mission/objectives of the ACTG. The investigators will initiate and participate in clinical trials of promising new antiretroviral compounds and immune-based therapies designed to interfere with the virus life cycle. Within this context they will endeavor to learn more about HIV pathogenesis and the virologic, immunologic, or host factors that influence clinical outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI039156-03
Application #
2633568
Study Section
Special Emphasis Panel (SRC (56))
Project Start
1996-01-01
Project End
1999-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Mavura, Daudi R; Masenga, E John; Minja, Eli et al. (2015) Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania. Int J Dermatol 54:68-73
Scott, Lesley E; Crump, John A; Msuya, Emma et al. (2011) Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction. J Virol Methods 172:78-80
Crump, John A; Ramadhani, Habib O; Morrissey, Anne B et al. (2011) Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. Trop Med Int Health 16:830-7
Tribble, A C; Hamilton, C D; Crump, J A et al. (2009) Missed opportunities for diagnosis of tuberculosis and human immunodeficiency virus co-infection in Moshi, Tanzania. Int J Tuberc Lung Dis 13:1260-6
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Seshadri, C; Uiso, L O; Ostermann, J et al. (2008) Low sensitivity of T-cell based detection of tuberculosis among HIV co-infected Tanzanian in-patients. East Afr Med J 85:442-9
Tebas, Pablo; Henry, William Keith; Matining, Roy et al. (2008) Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One 3:e2021
Landman, Keren Z; Ostermann, Jan; Crump, John A et al. (2008) Gender differences in the risk of HIV infection among persons reporting abstinence, monogamy, and multiple sexual partners in northern Tanzania. PLoS One 3:e3075
Hare, C Bradley; Mellors, John; Krambrink, Amy et al. (2008) Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 47:421-4

Showing the most recent 10 out of 41 publications